Analyst firms · Barclays · TARS
Barclays TARS price target and rating history
Tarsus Pharmaceuticals Inc. (TARS) · Health Care
Barclays rates Tarsus Pharmaceuticals Inc. (TARS) Overweight with a $110 price target, as of its latest action on Sep 16, 2026. It has published 3 rating actions on TARS since August 2022, including 0 upgrades and 0 downgrades. Across 4 firms with a TARS price target in the last 12 months, the median target is $105. Barclays's $110 is 5% above that.
- Current rating
- Overweight
- Price target
- $110
- Median target, all firms
- $105
- Actions on TARS
- 3
Barclays price target on TARS
Every Barclays rating on TARS
- Sep 16, 2026
- Dec 9, 2025
- Aug 1, 2022
How other firms rate TARS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Goldman Sachs | Buy | $116 | Sep 24, 2026 |
| Barclays | Overweight | $110 | Sep 16, 2026 |
| Oppenheimer | Outperform | $98 | Apr 24, 2026 |
| Mizuho | Outperform | $100 | Nov 20, 2025 |
Questions about Barclays and TARS
- What is Barclays's price target for TARS?
- Barclays's latest stated price target for Tarsus Pharmaceuticals Inc. (TARS) is $110, from its action on Sep 16, 2026.
- What is Barclays's rating on TARS?
- Barclays rates TARS Overweight, a bullish rating, as of Sep 16, 2026.
- When did Barclays last change its view on TARS?
- On Sep 16, 2026, Barclays resumes coverage at Overweight, price target $110.
- How does Barclays's TARS target compare with other analysts?
- Across 4 firms with a TARS price target in the last 12 months, the median target is $105. Barclays's $110 is 5% above that.
More TARS rating histories
All Barclays ratingsTARS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.